Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 112 Matches

Indinavir

Model Files Publication

Brand Name(s) include: Crixivan

Disease: HIV

Drug Class: Protease inhibitor

Date of Review: 2020

Number of Models Reviewed: 1

Number of Models added to the Repository: 1

The model at-a-glance

Publication	Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e3.
Simcyp Version	V13
Published Model Application	Prediction of exposure in pregnancy
Absorption Model	First Order
Volume of Distribution Details	Full PBPK
Route of Elimination	CYP3A4 and renal clearance Nonlinear CYP3A4 kinetics
Perpetrator DDI	None
Advantages and Limitations	Model developed in healthy volunteers to simulate indinavir PK in pregnant women. Can simulate iv and oral data. Verified in healthy subjects and pregnant women in the third trimester. Fm_CYP3A4 not verified with clinical data.
Model Compound Files	v18_res_indinavir_simcyp_ke

Search Score: 2

Rosuvastatin_Itraconazole_OH-Itraconazole_V19R1_Pfizer_20210804

Model Files Publication

An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Itraconazole. Link to the publication with further details: http://doi.org/10.1002/psp4.12672

Search Score: 2

ItraconazoleAndTwoMetabolites_V17R1_AstraZeneca_20191113

Model Files Publication

Capsule and solution formulation of itraconazole in different compound files. 2 Metabolites: OH-itraconazole and KETO-itraconazole. Note: If you wish to add both itraconazole metabolites then itraconazole has to be placed as substrate. https://doi.org/10.1124/dmd.118.081364

Search Score: 2

Chloroquine_V18R2_PekingUniversityThirdHospital_20200317

Model Files Publication

A perfusion limited full PBPK model of chloroquine published in Clin Inf Dis in 2020, the model includes an additional organ that can be used to represent lung tissue accumulation of the drug. Please note a custom dosing for 66 days has been included in the file.

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Indinavir

The model at-a-glance

Rosuvastatin_Itraconazole_OH-Itraconazole_V19R1_Pfizer_20210804

ItraconazoleAndTwoMetabolites_V17R1_AstraZeneca_20191113

Chloroquine_V18R2_PekingUniversityThirdHospital_20200317

Your Privacy